Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.
Initial experimentations already showed promising results. The team will now embark on a three-year-long study of this device on people suffering from chronic insomnia to test the efficiency of the ...
CBD may help reduce chronic pain by targeting endocannabinoid receptor activity ... Like antidepressant medications, it appears to alter serotonin levels in the brain. Insomnia: Although early ...
The Princeton Psychotherapy Center, a leading provider of mental health care, is now offering specialized therapy options to help individuals struggling with social anxiety and insomnia. The center ...